EuroPCR 2023 |TAVR in Cardiogenic Shock

Patients presenting aortic stenosis with cardiogenic shock are at extreme risk, with 70% mortality until the aortic obstruction is resolved, and taking into account they make poor transplant candidates. Safety and efficacy of TAVR in patients with cardiogenic shock remains unclear.

The aim of this study was to assess events in patients undergoing TAVR with balloon expandable valves (SAPIEN 3 and SAPIEN 3 Ultra). 

Populations were matched with propensity score. Primary end point was inhospital all-cause mortality, at 30 days and one year, and major complications in the same period of time. 

Data from 4952 patients with cardiogenic shock were obtained. Mean age was 75.6 year with mean ejection fraction of 39.9%. observed complications were annulus rupture in 0.3%, aortic dissection in 0.2%, 0.4% coronary obstruction, 1% cardiac perforation, 0.2% devise embolization and 0.7% conversion to open surgery. 

Compared against the matched cohort with no cardiogenic shock, there was more inhospital mortality (9.9% vs 2.7%, P<0.0001), stroke (2.9% vs 1.5%; P<0.0001), vascular complications (2.3% vs 1.3%, P<0.0001) and major bleeding (2.5% vs 0.7%, P<0.0001). 

At one year, were was 29.7% mortality vs 22.6% in patients with no cardiogenic shock (HR 1.57, CI 95% 1.43-1.72, P<0.001). After multivariable analysis, predictors of mortality at 30 days were dialysis, pacemaker implantation, assisting device requirement, and peripheral vascular disease. 

Read also: EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves.

The author concluded that TAVR was effective and safe in the context of cardiogenic shock with acceptable events at 30 days and one year. These outcomes observed in a registry should suggest “primary” TAVR as the best strategy for patients with aortic stenosis leading to cardiogenic shock. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Abhijeet Dhoble at Late Breaking Trials Sessions, EuroPCR 2023, May 16, 2023, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

T-TEER: Beyond Traditional Pulmonary Hypertension Thresholds

Significant tricuspid regurgitation (TR) is associated with progressive functional deterioration, heart failure (HF) hospitalizations, and increased mortality. In recent years, transcatheter tricuspid edge-to-edge repair...

Is left atrial appendage closure safe in patients with reduced ejection fraction?

Patients with heart failure with reduced ejection fraction (HFrEF) were excluded from the major randomized trials evaluating percutaneous left atrial appendage closure (LAAC), and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SPYRAL Program: 3-Year Outcomes in Patients Treated with Renal Denervation

Hypertension is the leading modifiable risk factor for cardiovascular disease and remains a major global health challenge, affecting more than one billion adults worldwide.  Despite...

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...